This is mainly due in one hand to the large inter-observer variability in assessment of the percentage of this marker, and in the other hand to the fact that clinical decision-making regarding treatment options in breast cancer often relies on the application of a Ki 67 cutoff to classify patients into “Ki67 high” or “Ki67 low” risk groups, however widely varying cutoff values (ranging from 0 to 28.6%) have been used to define the group with high Ki 67 [21, 22]. The gene discussed is MKI67; the disease is breast carcinoma.